Table 4.
The correlations between PD1/PDL1 expression and CD8+T cells density at different locations in MSI and MSS GC
| MSI-CD8 | MSS-CD8 | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tumor center (%) | Invasive front (%) | Tumor center (%) | Invasive front (%) | |||||||||||||
| Low (%) |
High (%) |
Sum | P | Low (%) |
High (%) |
Sum | P | Low (%) |
High (%) |
Sum | P | Low (%) |
High (%) |
Sum | P | |
| PD1 | 0.550 | 0.031 | 0.381 | 0.163 | ||||||||||||
| Negative | 9(47) | 10(39) | 19 | 12(60) | 7(28) | 19 | 49(58) | 37(51) | 86 | 49(60) | 37(49) | 86 | ||||
| Positive | 10(53) | 16(61) | 26 | 8(40) | 18(72) | 26 | 36(42) | 36(49) | 72 | 33(40) | 39(51) | 72 | ||||
| Sum | 19(100) | 26(100) | 45 | 20(100) | 25(100) | 45 | 85(100) | 73(100) | 158 | 82(100) | 76(100) | 158 | ||||
| PDL1[T] | 0.831 | 0.832 | 0.691 | 0.427 | ||||||||||||
| Negative | 13(68) | 17(65) | 30 | 13(65) | 17(68) | 30 | 64(76) | 56(79) | 120 | 64(80) | 56(75) | 120 | ||||
| Positive | 6(32) | 9(35) | 15 | 7(35) | 8(32) | 15 | 20(24) | 15(21) | 35 | 16(20) | 19(25) | 35 | ||||
| Sum | 19(100) | 26(100) | 45 | 20(100) | 25(100) | 45 | 84(100) | 71(100) | 155 | 80(100) | 75(100) | 155 | ||||
| PDL1 | 0.345 | 0.947 | 0.148 | 0.743 | ||||||||||||
| Negative | 10(53) | 10(39) | 20 | 9(45) | 11(44) | 20 | 46(55) | 47(66) | 93 | 49(61) | 44(59) | 93 | ||||
| Positive | 9(47) | 16(61) | 25 | 11(55) | 14(56) | 25 | 38(45) | 24(34) | 62 | 31(39) | 31(41) | 62 | ||||
| Sum | 19(100) | 26(100) | 45 | 20(100) | 25(100) | 45 | 84(100) | 71(100) | 155 | 80(100) | 75(100) | 155 | ||||
GC: gastric cancer; MSI: microsatellite unstable; MSS: microsatellite stable; CD68+ M: CD68+ macrophage; PD1: programmed cell death protein 1; PDL1, programmed death ligand 1; In all 215 cases of gastric cancer, 203 cases immunohistochemical sections were evaluable for PD1 and CD8 simultaneously in tumor center and invasive front, 200 cases for PDL1 [T]/PDL1 and CD8 simultaneously in tumor center and invasive front.